Estrella Immunopharma Stock (NASDAQ:ESLA)

Ownership Financials Chart

Previous Close

$1.01

52W Range

$0.81 - $20.80

50D Avg

$1.36

200D Avg

$1.18

Market Cap

$40.01M

Avg Vol (3M)

$92.31K

Beta

0.19

Div Yield

-

ESLA Company Profile

Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. is based in EmeryVille, California.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

-

IPO Date

Sep 14, 2021

Website

ESLA Performance

ESLA Financial Summary

	Dec 22	Jun 22	Jun 21
Revenue	-	-	-
Operating Income	$-1.57M	$-1.69M	$-733.69K
Net Income	$-996.10K	$-1.69M	$-733.69K
EBITDA	$-1.57M	$-1.69M	$-733.69K
Basic EPS	$-0.17	$-0.29	$-0.02
Diluted EPS	$-0.17	$-0.29	$-0.02

Fiscal year ends in Dec 22 | Currency in USD